ezlopitant has been researched along with (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid in 1 studies
Studies (ezlopitant) | Trials (ezlopitant) | Recent Studies (post-2010) (ezlopitant) | Studies ((6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid) | Trials ((6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid) | Recent Studies (post-2010) ((6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid) |
---|---|---|---|---|---|
22 | 2 | 1 | 32 | 0 | 12 |
Protein | Taxonomy | ezlopitant (IC50) | (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid (IC50) |
---|---|---|---|
3-hydroxy-3-methylglutaryl-coenzyme A reductase | Homo sapiens (human) | 0.0142 | |
Cytochrome P450 2C9 | Homo sapiens (human) | 0.4 | |
Insulin receptor | Rattus norvegicus (Norway rat) | 0.0004 | |
Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.0004 | |
3-hydroxy-3-methylglutaryl-coenzyme A reductase | Rattus norvegicus (Norway rat) | 0.003 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Jolivette, LJ; Nagilla, R; Ward, KW | 1 |
1 other study(ies) available for ezlopitant and (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
Article | Year |
---|---|
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
Topics: Administration, Oral; Animals; Area Under Curve; Dogs; Haplorhini; Humans; Models, Statistical; Rats; Software; Species Specificity; Xenobiotics | 2005 |